News

No Picture
News

At two-year follow-up, Evrysdi continues to show numerical improvements in data, Roche says

September 28, 2020 San Francisco Biotechnology Network News Comments Off on At two-year follow-up, Evrysdi continues to show numerical improvements in data, Roche says

A little less than two months after receiving an FDA approval in spinal muscular atrophy, Roche’s Genentech continues to roll out data for risdiplam.
The drug, marketed as Evrysdi in the US, showed improved motor functions in infants as part of a two-y… […]

No Picture
News

Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19

September 28, 2020 PR Newswire Releases Comments Off on Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19

PALO ALTO, Calif., Sept. 28, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced results of an investigat… […]

No Picture
News

Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA’s CRL

September 28, 2020 San Francisco Biotechnology Network News Comments Off on Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA’s CRL

The FDA’s recent slapdown of Gilead’s rheumatoid arthritis JAK filgotinib didn’t even slightly delay its arrival in 2 big world markets. The EC stamped its marketing authorization on the blockbuster candidate at the end of the week, following the news … […]

No Picture
News

Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)

September 28, 2020 San Francisco Biotechnology Network News Comments Off on Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with symptom… […]

No Picture
News

TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)

September 28, 2020 PR Newswire Releases Comments Off on TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of o… […]

No Picture
News

TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)

September 28, 2020 PR Newswire Releases Comments Off on TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2020 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of o… […]